Mannkind Corporation Intrinsic Stock Value – MANNKIND CORPORATION Reports Second Quarter Earnings Results for FY2023

August 14, 2023

🌥️Earnings Overview

MANNKIND ($NASDAQ:MNKD): MannKIND Corporation reported their second quarter FY2023 earnings results ending June 30 2023 on August 7 2023. This quarter saw a total revenue of USD 48.6 million, a 157.3% increase compared to the same quarter in the previous year. However, net income declined 81.7% and amounted to USD -5.3 million compared to the same period in the preceding year.

Price History

Stock opened at $4.7 and closed at $4.6, down by 2.5% from the prior closing price of $4.7. Despite the decrease in share price, analysts were still pleased with the overall performance of the company. The company attributed the decrease in earnings to increased spending on research and development as part of their commitment to remain competitive in the industry. Overall, MANNKIND CORPORATION‘s performance was seen as a positive sign for investors, as they had recently been underperforming relative to competitors.

The company is continuing to invest in its future growth while also aiming to reduce expenses in order to maximize shareholder value. With the right strategies and long-term investments, MANNKIND CORPORATION can look forward to a bright future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Mannkind Corporation. More…

    Total Revenues Net Income Net Margin
    158.12 -47.44 -28.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Mannkind Corporation. More…

    Operations Investing Financing
    -26.7 59.81 17.56
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Mannkind Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    313.42 573.91 -0.97
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Mannkind Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    36.7% -14.1%
    FCF Margin ROE ROA
    -36.2% 5.4% -4.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Mannkind Corporation Intrinsic Stock Value

    At GoodWhale, we have been analyzing the financials of MANNKIND CORPORATION to help investors make informed decisions. Our proprietary Valuation Line has determined the intrinsic value of MANNKIND CORPORATION’s shares to be around $7.0. Currently, the stock is trading at $4.6, meaning investors have the opportunity to purchase shares at 34.1% below the intrinsic value. This could be a great opportunity for investors looking for discounts on high-quality stocks. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    It is one of the most influential companies in the sector, competing with other major players such as Regnum Corp, Blueprint Medicines Corp, and 180 Life Sciences Corp. These companies have become industry leaders in the development of innovative treatments that are aimed at improving patient lives.

    – Regnum Corp ($OTCPK:RGMP)

    Regnum Corp is a privately held company that provides financial services for its clients. It has a market capitalization of 3.1 million as of 2022, indicating that the company’s stock is highly valued. Additionally, the company has a Return on Equity (ROE) of 57.64%, illustrating that the company is able to generate significant returns on shareholder equity. This indicates that the company is effectively utilizing its resources and is well-positioned to continue growing into the future.

    – Blueprint Medicines Corp ($NASDAQ:BPMC)

    Blueprint Medicines Corp is a biopharmaceutical company focused on developing targeted therapies for people living with rare diseases and cancer. The company has a market cap of 2.51B as of 2022, indicating it’s size relative to other companies in the industry. Despite its size, Blueprint Medicines Corp has a negative Return on Equity of -63.38%, indicating that the company is not generating profits from its investments. This could be due to the company’s focus on research and development of new treatments and therapies, which require large upfront investments that may not pay off for some time.

    – 180 Life Sciences Corp ($NASDAQ:ATNF)

    Life Sciences Corp is a biotechnology company that specializes in the development of innovative therapies and technologies to treat diseases. The company’s market capitalization as of 2022 is 7.29M, which indicates that it is a small-cap stock. The return on equity (ROE) for Life Sciences Corp is -28.89%, which is an indication that the company has been unable to generate a profit from its investments. This could be due to the fact that the company is new and is still in the process of developing its products. The negative ROE also implies that the company has been unable to generate sufficient revenue to cover its expenses. However, with time, the company may be able to increase its ROE if it can effectively market and sell its products.


    Mannkind Corporation reported strong financial results for the second quarter of FY2023, with total revenue for the quarter coming in at USD 48.6 million, up 157.3% year-on-year. Despite this impressive top-line growth, net income for the quarter declined 81.7% year-on-year to USD -5.3 million. Investors should closely monitor the company’s progress towards profitability, as well as their ongoing ability to drive revenue growth and reduce costs. Any positive developments in these areas could have a positive effect on the stock price in the future.

    Recent Posts

    Leave a Comment